Oncology news

20-04-2016 | Melanoma | Main feed | Article
Editor's pick

KEYNOTE-001 findings add support to pembrolizumab for advanced melanoma

A third of patients with advanced or metastatic melanoma will achieve an objective response to treatment with the programmed cell death protein inhibitor pembrolizumab, suggest KEYNOTE-001 findings, regardless of whether they have previously been treated with ipilimumab.


JAMA 2016; 315: 1573–1575, 600–1609

04-05-2016 | Oncology | News | Article
News in brief

Mental disorder risk increase begins at cancer diagnosis workup

Research in JAMA Oncology highlights the need for psychological management and support as early during the course of cancer as the initial workup leading to a diagnosis.

04-05-2016 | Non-small-cell lung cancer | News | Article

NSCLC MAGE-A3 immunotherapy development halted

Disease-free survival is not prolonged with adjuvant MAGE-A3 immunotherapy in patients with surgically resected non-small-cell lung cancer, according to a placebo-controlled trial.


Lancet Oncol 2016; Advance online publication

28-04-2016 | Breast cancer | News | Article
News in brief

Anthracycline-related cognitive dysfunction concerns disputed

The authors of a research letter find no association between anthracycline-based chemotherapy and decline in neurocognitive function among breast cancer survivors, in contrast to another recent study.

27-04-2016 | HBV | News | Article

HBcrAg may predict HCC development

Research suggests a role for hepatitis B core-related antigen in the prediction of hepatocellular carcinoma development in nucleos(t)ide analogue treatment-naïve patients with chronic hepatitis B virus infection.


J Hepatol 2016; Advance online publication

KEYNOTE-012 Triple-Negative Breast Cancer, Gastric Cancer Results Suggest Pembrolizumab Potential

Patients with advanced programmed death-ligand 1-positive triple-negative breast cancer or gastric cancer may benefit from pembrolizumab therapy

Read the full story on ESMO's oncologyPRO educational website (for registered ESMO members).

approvalsWatch: Oncology



medwireNews brings you coverage of the 2015 European Cancer Congress, held in Vienna, Austria.

Click through to read the full reports of the latest research.

Twitter Icon Follow medwireNews

Click here
image credits